RECRUITINGINTERVENTIONAL

Brain Stimulation to the Hippocampus in Schizophrenia

Theta Burst Modulation of Hippocampal-Cortical Rhythms in Schizophrenia

About This Trial

Schizophrenia - marked by delusions, hallucinations, and cognitive deficits - causes the most disability of any mental health condition, but existing treatments have significant side effect burden and are often ineffective. Disordered neural activity in the hippocampus likely contributes to schizophrenia symptoms, but to develop better therapies we need to understand whether hippocampal activity in schizophrenia can be systematically affected by non-invasive brain stimulation techniques like transcranial magnetic stimulation (TMS). This proposal will investigate the use of connectivity-guided theta burst brain stimulation to specifically target hippocampal function in schizophrenia, offering insights into fundamental hippocampal processes, schizophrenia pathophysiology, and potential avenues to use brain stimulation as a therapeutic tool in this devastating illness.

Who May Be Eligible (Plain English)

Who May Qualify: - Men and women, ages 18 to 65 years - Medically intractable epilepsy requiring phase II monitoring (intracranial EEG arms only) - DSM-V diagnosis of schizophrenia spectrum Axis I disorders including delusional disorder, brief psychotic disorder, schizophreniform disorder, schizophrenia, schizoaffective disorder (non-invasive TMS-EEG arms only). - Must have intellectual capacity to ensure adequate comprehension of the study and potential risks involved in order to provide willing to sign a consent form - No current or history of major neurological disorders other than epilepsy. Who Should NOT Join This Trial: - DSM5 diagnosis of intellectual disability - Significant head injury - Active suicidal ideation or history of suicide attempt within the past 1 year. - Medical illness affecting brain structure or function, or other uncontrolled or unstable medical condition. - Pregnancy or postpartum (\<6 weeks after delivery or miscarriage) - Inability to provide willing to sign a consent form - Active substance abuse other than alcohol or cannabis within the past 1 year - Psychotic illness with a temporal relation to substance use or head injury - Those with a contraindication for MRIs or TMS (e.g. implanted metal). Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Men and women, ages 18 to 65 years * Medically intractable epilepsy requiring phase II monitoring (intracranial EEG arms only) * DSM-V diagnosis of schizophrenia spectrum Axis I disorders including delusional disorder, brief psychotic disorder, schizophreniform disorder, schizophrenia, schizoaffective disorder (non-invasive TMS-EEG arms only). * Must have intellectual capacity to ensure adequate comprehension of the study and potential risks involved in order to provide informed consent * No current or history of major neurological disorders other than epilepsy. Exclusion Criteria: * DSM5 diagnosis of intellectual disability * Significant head injury * Active suicidal ideation or history of suicide attempt within the past 1 year. * Medical illness affecting brain structure or function, or other uncontrolled or unstable medical condition. * Pregnancy or postpartum (\<6 weeks after delivery or miscarriage) * Inability to provide informed consent * Active substance abuse other than alcohol or cannabis within the past 1 year * Psychotic illness with a temporal relation to substance use or head injury * Those with a contraindication for MRIs or TMS (e.g. implanted metal).

Treatments Being Tested

DEVICE

Intracranial electrodes

Intracranial electrodes will be used for the delivery of invasive electrical brain stimulation.

DEVICE

TMS

TMS will be used for the delivery of noninvasive brain stimulation

DEVICE

TMS sham

Sham TMS will be used as a comparator for noninvasive brain stimulation

Locations (1)

Stanford University

Stanford, California, United States